Lowest Price Guaranteed From USD 4,499
Published
November 2019
Pages
528
View Count
15532
Example Insights
Report Description
[COVID-19 SERIES] The global market for novel vaccine delivery devices is projected to grow to $1.5 billion by 2030. According to experts, the global vaccines market is anticipated to generate revenues worth USD 100 billion by 2025. Data presented by the WHO indicates that the current global vaccination coverage is nearly 85%; this is believed to be responsible for preventing close to three million deaths from diseases, such as diphtheria, tetanus, whooping cough and measles. Recent global immunization records indicate that more than 115 million children were immunized against diphtheria, tetanus and pertussis in 2018. Given the rate at which the global population is growing, the demand for vaccines is likely to increase significantly. However, biopharmaceutical developers are plagued by concerns related to storage and handling of such preventive / therapeutic products. One commonly reported issue is related to vaccine administration. Despite the success of conventional delivery approaches, which rely on the intramuscular and subcutaneous routes of administration, the present scenario dictates that further improvements are required in order to deal with challenges related to large scale immunization initiatives. Some of the commonly reported disadvantages of the conventional (parenteral) mode of delivery include pain during administration, risk of cross contamination, needlestick injuries, and inaccurate dosing.
Of late, there has been an evident shift in interest to non-invasive immunization methods, which include oral, intranasal and transdermal modes of administration. Currently, many biopharmaceutical companies and clinical research institutes are engaged in the development of novel vaccine delivery systems, taking into consideration the specific requirements of large scale immunization initiatives. As a result, significant efforts have been put into the development of drug delivery technologies / devices, such as microneedle patches, electroporation-based needle free injection systems, jet injectors, inhalation-based delivery systems, biodegradable implants and certain novel types of oral delivery systems. It is worth highlighting that most of the aforementioned systems are specifically being designed to facilitate pain-free administration of vaccines and allow self-administration. Additionally, these novel vaccine delivery devices can play an important role in vaccination during the event of disease outbreaks / pandemics (such as the one being faced due to the novel coronavirus / COVID-19), where medical centers may not be equipped to deal with large scale immunization campaigns. Vaccine developers are also attempting to devise ways to make such products more stable so as to eliminate the need for cold chain in transporting such products. Given the pace of innovation in this field, it is anticipated that the novel vaccine delivery devices market is likely to witness radical changes in the coming years.
The “Novel Vaccine Delivery Devices Market, 2019-2030” report features an extensive study of the current landscape and the likely future opportunities associated with novel vaccine delivery devices, over the next 10-12 years. Amongst other elements, the report includes:
One of the key objectives of the report was to estimate the existing market size and assess potential future growth opportunities for novel vaccine delivery devices. Based on various parameters, such as number of marketed / pipeline products, price of devices (for commercially available products only) and estimated annual adoption rate, we have developed an informed estimate on the likely evolution of the market over the period 2019-2030. In addition, we have provided the likely distribution of the current and forecasted opportunities across [A] type of device (electroporation-based needle free injection systems, oral delivery systems, nasal delivery systems, jet injectors, microneedle patches and microinjectors), [B] route of administration (oral, intramuscular, intranasal, intradermal and subcutaneous), [C] type of vaccine (Bivalent Oral Polio Vaccine, BCG Vaccine, DTP-HepB-Hib Vaccine, Pneumococcal Conjugate Vaccine, Influenza Vaccine, Measles Vaccine, Tetanus-Diphtheria Vaccine and Others) and [D] key geographical regions (North America, Europe, Asia and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the current scenario within the novel vaccine delivery devices market and describes its evolution in the short-mid term and long term.
Chapter 3 provides a general introduction to vaccines along with information on classification of such preventive / therapeutic products. It also includes an overview of the various expression systems used in the development and manufacturing of vaccines and a discussion on various routes of administration. It features brief descriptions of various novel vaccine delivery devices and concludes with a discussion on the existing challenges and future trends that are likely to impact this emerging market segment.
Chapter 4 provides a detailed overview of the overall landscape of novel vaccine delivery devices that are developed / being developed for administration of various vaccines. It features an in-depth analysis of the devices, based on a number of parameters, such as details on type of device (autoinjectors, microneedle patches, jet injectors, dry powder inhalers, microinjectors, nasal delivery systems, pen injectors, biodegradable implants, electroporation-based needle free injection systems and novel oral delivery systems), route of administration (subcutaneous, transdermal, intramuscular, intradermal, inhalation, intranasal, and oral), drug delivery mechanism (mechanical, electrical and miscellaneous), nature of vaccine administration (invasive and non-invasive), speed of administration (fast, moderate and slow), self-administration potential, provisions for audio / visual feedback, device usability (disposable and reusable), type of needle (needleless, fixed needle, detachable needle, and hidden needle), and current development status of novel vaccine delivery systems (preclinical / discovery, clinical and marketed). In addition, the chapter provides information on drug developer(s), highlighting year of establishment, location of headquarters and strength of employee base.
Chapter 5 features a product competitiveness analysis of novel vaccine delivery devices, based on the supplier power and product specifications. The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry.
Chapter 6 provides detailed assessment to evaluate the effectiveness of various vaccines delivery devices to compare their strengths and capabilities for vaccine administration; the analysis is based on a variety of relevant parameters, such as type of active ingredient, dosage form, route of administration, target disease indication and target patient population.
Chapter 7 presents a list of marketed and pipeline vaccines that are likely to be considered for delivery via novel vaccine delivery devices in the future. The list was compiled considering various parameters, such as type of active ingredient, dosage form, route of administration, target disease indication and target patient population. For the purpose of this analysis, we collated a list of over 490 marketed and clinical vaccines. The likelihood of delivery via novel vaccine delivery devices in the future was estimated using the weighted average of the aforementioned parameters.
Chapter 8 provides detailed profiles of key novel vaccine delivery device developers. Each profile presents a brief overview of the company, its financial information (if available), information on its product portfolio, recent developments and an informed future outlook.
Chapter 9 features an elaborate analysis and discussion of the various collaborations and partnerships related to the novel vaccine delivery devices, which have been inked amongst players. It includes a brief description of the purpose of the partnership models (including R&D agreements, product development, licensing, distribution, research agreements, manufacturing agreements, acquisitions, product development and commercialization and others) that have been adopted by the stakeholders in this domain, since 2014. It consists of a schematic representation showcasing the players that have forged the maximum number of alliances. Furthermore, we have provided a world map representation of the deals inked in this field, highlighting those that have been established within and across different continents.
Chapter 10 provides a discussion on important industry-specific trends, key market drivers and challenges, under a SWOT framework, featuring a qualitative Harvey ball analysis, that highlights the relative impact of each SWOT parameter on the overall medical device label manufacturing industry.
Chapter 11 presents an insightful market forecast analysis, highlighting the future potential of novel vaccine delivery devices market, till the year 2030. We have segregated the opportunity of novel vaccine delivery devices on the basis of different types of device (electroporation-based needle free injection systems, oral delivery systems, nasal delivery systems, jet injectors, microneedle patches and microinjectors), route of administration (oral, intramuscular, intranasal, intradermal and subcutaneous, type of vaccine (Bivalent Oral Polio Vaccine, BCG Vaccine, DTP-HepB-Hib Vaccine, Pneumococcal Conjugate Vaccine, Influenza Vaccine, Measles Vaccine, Tetanus-Diphtheria Vaccine and Others) and key geographical regions (North America, Europe, Asia and rest of the world).
Chapter 12 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of interviews held with Michael Schrader (Chief Executive Officer and Founder, Vaxess Technologies), Mikael Ekstrom and Roger Lassing (Vice President, Business Development, Iconovo) and Henry King (Market Intelligence and Business Development Manager, Innoture).
Chapter 13 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of this segment of the novel vaccine delivery devices industry.
Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures included in the report.
Chapter 15 is an appendix, which contains a list of companies and organizations mentioned in this report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. An Overview of Vaccines
3.1.1. Classification of Vaccines
3.1.1.1. Live, Attenuated Vaccines
3.1.1.2. Inactivated Vaccines
3.1.1.3. Subunit Vaccines
3.1.1.4. Toxoid Vaccines
3.1.1.5. DNA Vaccines
3.1.2. Key Components of Vaccine Formulations
3.1.3. Production of Vaccines in Different Expression Systems
3.1.3.1. Embryonated Chicken Eggs and Primary Chicken Embryonic Fibroblasts (CEFs)
3.1.3.2. Mammalian Expression Systems
3.1.3.3. Avian Expression Systems
3.1.3.4. Plant Expression Systems
3.1.3.5. Bacterial Expression Systems
3.1.3.6. Yeast Expression Systems
3.1.3.7. Insect Expression System
3.1.4. Routes of Administration for Vaccines
3.1.4.1. Intradermal Route
3.1.4.2. Subcutaneous Route
3.1.4.3. Intramuscular Route
3.1.4.4. Oral Route
3.1.4.5. Intranasal Route
3.1.4.6. Inhalation
3.1.5. Key Challenges Associated with Vaccine Delivery
3.1.6. Novel Approaches for Vaccine Delivery Devices
3.1.6.1. Autoinjectors
3.1.6.2. Biodegradable Implants
3.1.6.3. Buccal / Sublingual Vaccine Delivery Systems
3.1.6.4. Electroporation
3.1.6.5. Inhalation / Pulmonary Vaccine Delivery Systems
3.1.6.6. Jet Injectors
3.1.6.7. Microinjection System
3.1.6.8. Novel Oral Vaccine Formulations
3.1.7. Future Perspectives
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Marketed Vaccines Landscape
4.3. Clinical-Stage Vaccines Landscape
4.4. Novel Vaccine Delivery Devices: Overall Market Landscape
4.4.1. Analysis by Type of Device
4.4.2. Analysis by Route of Administration
4.4.3. Analysis by Drug Delivery Mechanism
4.4.4. Analysis by Nature of Vaccine Administration
4.4.5. Analysis by Speed of Vaccine Administration
4.4.6. Analysis by Self-Administration Potential
4.4.7. Analysis by Availability of Audio / Visual Feedback
4.4.8. Analysis by Device Usability
4.4.9. Analysis by Type of Needle
4.4.10. Analysis by Stage of Development
4.5. Novel Vaccine Delivery Device Developers: Overall Market Landscape
4.5.1. Analysis by Type of Developer
4.5.2. Analysis by Year of Establishment
4.5.3. Analysis by Company Size
4.5.4. Analysis by Geographical Location
5. DEVICE COMPETITIVENESS ANALYSIS
5.1. Chapter overview
5.2. Assumptions and Methodology
5.2.1. Device Competitiveness Analysis: Competitive Landscape
6. TECHNOLOGY EFFECTIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Assumptions and Key Parameters
6.3. Methodology
6.4. Vaccine Delivery Devices: Technology Effectiveness Analysis
6.4.1. Devices for Marketed Vaccines
6.4.1.1. Analysis by Type of Active Ingredient
6.4.1.2. Analysis by Dosage Form
6.4.1.3. Analysis by Route of Administration
6.4.1.4. Analysis by Target Disease Indication
6.4.1.5. Analysis by Target Patient Population
6.4.2. Devices for Clinical-Stage Vaccines
6.4.2.1. Analysis by Type of Active Ingredient
6.4.2.2. Analysis by Dosage Form
6.4.2.3. Analysis by Route of Administration
6.4.2.4. Analysis by Target Disease Indication
6.4.2.5. Analysis by Target Patient Population
7. NOVEL VACCINE DELIVERY DEVICES: LIKELY VACCINE CANDIDATES
7.1. Chapter Overview
7.2. Methodology and Key Parameters
7.3. Marketed Vaccines
7.3.1. Electroporation-based Needle Free Injection Systems: Likely Vaccine
7.3.1.1. Most Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
7.3.1.2. Likely Candidates for Delivery via Electroporation-based Needle Free Injection SystemsSystems
7.3.1.3. Less Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
7.3.1.4. Least Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
7.3.2. Jet Injectors: Likely Vaccine Candidates
7.3.2.1. Most Likely Candidates for Delivery via Jet Injectors
7.3.2.2. Likely Candidates for Delivery via Jet Injectors
7.3.2.3. Less Likely Candidates for Delivery via Jet Injectors
7.3.2.4. Least Likely Candidates for Delivery via Jet Injector
7.3.3. Microneedle Patches: Likely Vaccine Candidates
7.3.3.1. Most Likely Candidates for Delivery via Microneedle Patches
7.3.3.2. Less Likely Candidates for Delivery via Microneedle Patches
7.3.3.3. Least Likely Candidates for Delivery via Microneedle Patches
7.3.4. Nasal delivery Systems: Likely Vaccine Candidates
7.3.4.1. Most Likely Candidates for Delivery via Nasal Delivery Systems
7.3.4.2. Likely Candidates for Delivery via Nasal Delivery Systems
7.3.4.3. Less Likely Candidates for Delivery via Nasal Delivery Systems
7.3.4.4. Least Likely Candidates for Delivery via Nasal Delivery Systems
7.3.5. Oral Delivery Systems for Liquid Formulations: Likely Vaccine Candidates
7.3.5.1. Most Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
7.3.5.2. Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
7.3.5.3. Less Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
7.3.5.4. Least Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
7.3.6. Oral Delivery Systems for Solid Formulations: Likely Vaccine Candidates
7.3.6.1. Most Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
7.3.6.2. Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
7.3.6.3. Less Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
7.3.6.4. Least Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
7.3.7. Prefilled Syringes: Likely Vaccine Candidates
7.3.7.1. Most Likely Candidates for Delivery via Prefilled Syringes
7.3.7.2. Likely Candidates for Delivery via Prefilled Syringes
7.3.7.3. Less Likely Candidates for Delivery via Prefilled Syringes
7.3.7.4. Least Likely Candidates for Delivery via Prefilled Syringes
7.4. Clinical-Stage Vaccines
7.4.1. Electroporation-based Needle Free Injection Systems: Likely Vaccine Candidates
7.4.1.1. Most Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
7.4.1.2. Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
7.4.1.3. Less Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
7.4.1.4. Least Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
7.4.2. Jet Injectors: Likely Vaccine Candidates
7.4.2.1. Most Likely Candidates for Delivery via Jet Injectors
7.4.2.2. Likely Candidates for Delivery via Jet Injectors
7.4.2.3. Less Likely Candidates for Delivery via Jet Injectors
7.4.2.4. Least Likely Candidates for Delivery via Jet Injectors
7.4.3. Microneedle Patches: Likely Vaccine Candidates
7.4.3.1. Most Likely Candidates for Delivery via Microneedle Patches
7.4.3.2. Likely Candidates for Delivery via Microneedle Patches
7.4.3.3. Less Likely Candidates for Delivery via Microneedle Patches
7.4.3.4. Least Likely Candidates for Delivery via Microneedle Patches
7.4.4. Nasal Delivery Systems: Likely Vaccine Candidates
7.4.4.1. Most Likely Candidates for Delivery via Nasal Delivery Systems
7.4.4.2. Likely Candidates for Delivery via Nasal Delivery Systems
7.4.4.3. Less Likely Candidates for Delivery via Nasal Delivery Systems
7.4.4.4. Least Likely Candidates for Delivery via Nasal Delivery Systems
7.4.5. Oral Delivery Systems for Liquid Formulations: Likely Vaccine Candidates
7.4.5.1. Most Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
7.4.5.2. Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
7.4.5.3. Less Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
7.4.5.4. Least Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
7.4.6. Oral Delivery Systems for Solid Formulations: Likely Vaccine Candidates
7.4.6.1. Most Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
7.4.6.2. Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
7.4.6.3. Less Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
7.4.6.4. Least Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
7.4.7. Prefilled Syringes: Likely Vaccine Candidates
7.4.7.1. Most Likely Candidates for Delivery via Prefilled Syringes
7.4.7.2. Likely Candidates for Delivery via Prefilled Syringes
7.4.7.3. Less Likely Candidates for Delivery via Prefilled Syringes
7.4.7.4. Least Likely Candidates for Delivery via Prefilled Syringes
8. COMPANY PROFILES
8.1. Company Overview
8.2. 3M
8.2.1. Company Overview
8.2.2. Financial Information
8.2.3. Product Portfolio
8.2.3.1. 3M™ Hollow Microstructured Transdermal System
8.2.3.2. 3M™ Solid Microneedle
8.2.4. Recent Collaborations
8.2.5. Future Outlook
8.3. Becton Dickinson
8.3.1. Company Overview
8.3.2. Financial Information
8.3.3. Product Portfolio
8.3.3.1. BD Intevia™ Handheld Autoinjector
8.3.3.2. BD Accuspray™ Nasal Spray System
8.3.4. Future Outlook
8.4. Consort Medical
8.4.1. Company overview
8.4.2. Financial Information
8.4.3. Technology Overview
8.4.4. Product Portfolio
8.4.4.1. Autoinjectors
8.4.4.1.1. Syrina
8.4.4.1.2. OTS Autoinjector
8.4.4.2. Nasal Delivery System
8.4.5. Recent Collaborations
8.4.6. Future Outlook
8.5. D'Antonio Consultants International
8.5.1. Company Overview
8.5.2. Product Portfolio
8.5.2.1. LectraJet® High Speed Jet Injection System
8.5.2.2. LectraJet® M3 RA Needle-Free Injection System
8.5.2.3. LectraJet® M4 RA Needle-Free Injection System
8.5.2.4. Multi-Channel Jet Injector
8.6. Enesi Pharma
8.6.1. Company Overview
8.6.2. Product Portfolio
8.6.2.1. Enesi ImplaVax®
8.6.3. Recent Collaborations
8.6.4. Future Outlook
8.7. Ichor Medical Systems
8.7.1. Company Overview
8.7.2. Product Portfolio
8.7.2.1. TriGrid® Delivery System
8.7.3. Recent Collaborations
8.7.4. Future Outlook
8.8. Iconovo
8.8.1. Company Overview
8.8.2. Financial Information
8.8.3. Product Portfolio
8.8.3.1. ICOres
8.8.3.2. ICOone
8.8.3.3. ICocap
8.8.3.4. ICopre
8.8.4. Recent Collaborations
8.8.5. Future Outlook
8.9. Inovio Pharmaceuticals
8.9.1. Company Overview
8.9.2. Financial Information
8.9.3. Product Portfolio
8.9.3.1. ZetaJet®
8.9.3.2. Biojector® 2000
8.9.3.3. CELLECTRA® Electroporation Delivery Device
8.9.4. Recent Collaborations
8.9.5. Future Outlook
8.10. PharmaJet
8.10.1. Company Profile
8.10.2. Product Portfolio
8.10.2.1. PharmaJet Stratis® Needle-Free Injector
8.10.2.2. PharmaJet Tropis® Intradermal Injection
8.10.3. Recent Collaborations
8.10.4. Future Outlook
8.11. Union Medico
8.11.1. Company Overview
8.11.2. Product Portfolio
8.11.2.1. 45Ëš Autoinjector
8.11.2.1.1. 45 Ëš/ S Autoinjector
8.11.2.1.2. 45 Ëš/ M Autoinjector
8.11.2.1.3. 45 Ëš/ R Autoinjector
8.11.2.2. 90ËšAutoinjector
8.11.2.2.1. 90 Ëš / S Autoinjector
8.11.2.2.2. 90 Ëš / M Autoinjector
8.11.2.2.3. 90 Ëš / XL Autoinjector
8.11.2.2.4. SuperGrip Autoinjector
8.11.2.2.5. Exclusive Autoinjector
8.11.3. Recent Development and Future Outlook
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Novel Vaccine Delivery Devices: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Type of Device
9.3.4. Analysis by Type of Partnership and Type of Device
9.3.5. Analysis by Type of Vaccine and Type of Device
9.3.6. Analysis by Type of Active Ingredient
9.3.7. Analysis by Target Disease Indication
9.3.8. Popular Vaccine Delivery Devices: Analysis by Number of Partnerships
9.3.9. Most Active Industry Players: Analysis by Number of Partnerships
9.3.10. Intercontinental and Intracontinental Agreements
10. SWOT ANALYSIS
10.1. Chapter Overview
10.2. Strengths
10.2.1. Minimally Invasive / Non-Invasive Vaccine Delivery
10.2.2. Ease of Use
10.2.3. Elimination of Cold-Chain Storage
10.2.4. Economic Advantages
10.2.5. Elimination of Medication Errors
10.3. Weaknesses
10.3.1. Manufacturing Complexities
10.3.2. Cost Concerns
10.3.3. Product Stability Concerns
10.4. Opportunities
10.4.1. Growing Pipeline of Vaccines
10.4.2. Increase in Self-Injecting Patient Population
10.4.3. Growing Incidence of Infectious Diseases
10.4.4. Innovation in Design and Technical Advancements
10.4.5. Geographic Expansions
10.5. Threats
10.5.1. Competition from Conventional Delivery Systems
10.5.2. Strict Regulatory Framework
10.6. Concluding Remarks
11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Forecast Methodology and Key Assumptions
11.3. Global Novel Vaccine Delivery Device Market, 2019-2030
11.3.1. Global Novel Vaccine Delivery Device Market, 2019-2030 (By Value)
11.3.1.1. Global Novel Vaccine Delivery Devices Market: Distribution by Type of Device, 2019-2030 (By Value)
11.3.1.2. Global Novel Vaccine Delivery Device Market: Distribution by Route of Administration 2019-2030 (By Value)
11.3.1.3. Global Novel Vaccine Delivery Device Market: Distribution by Type of Vaccine 2019-2030 (By Value)
11.3.1.4. Global Novel Vaccine Delivery Device Market: Distribution by Regions, 2019-2030 (By Value)
11.3.1.4.1. Novel Vaccine Delivery Devices Market in North America, 2019-2030 (By Value)
11.3.1.4.1.1. Novel Vaccine Delivery Devices Market in North America: Distribution by Type of Device, 2019-2030 (By Value)
11.3.1.4.1.2. Novel Vaccine Delivery Devices Market in North America: Distribution by Route of Administration, 2019-2030 (By Value)
11.3.1.4.1.3. Novel Vaccine Delivery Devices Market in North America: Distribution by Type of Vaccine, 2019-2030 (By Value)
11.3.1.4.2. Novel Vaccine Delivery Devices Market in Europe, 2019-2030 (By Value)
11.3.1.4.2.1. Novel Vaccine Delivery Devices Market in Europe: Distribution by Type of Device, 2019-2030 (By Value)
11.3.1.4.2.2. Novel Vaccine Delivery Devices Market in Europe: Distribution by Route of Administration, 2019-2030 (By Value)
11.3.1.4.2.3. Novel Vaccine Delivery Devices Market in Europe: Distribution by Type of Vaccine, 2019-2030 (By Value)
11.3.1.4.3. Novel Vaccine Delivery Devices Market in Asia Pacific, 2019-2030 (By Value)
11.3.1.4.3.1. Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Type of Device, 2019-2030 (By Value)
11.3.1.4.3.2. Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Route of Administration, 2019-2030 (By Value)
11.3.1.4.3.3. Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Type of Vaccine, 2019-2030 (By Value)
11.3.1.4.4. Novel Vaccine Delivery Devices Market in Rest of the World, 2019-2030 (By Value)
11.3.1.4.4.1. Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Type of Device, 2019-2030 (By Value)
11.3.1.4.4.2. Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Route of Administration, 2019-2030 (By Value)
11.3.1.4.4.3. Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Type of Vaccine, 2019-2030 (By Value)
11.3.2. Global Novel Vaccine Delivery Device Market, 2019-2030 (By Volume)
11.3.2.1. Global Novel Vaccine Delivery Device Market: Distribution by Type of Device, 2019-2030 (By Volume)
11.3.2.2. Global Novel Vaccine Delivery Device Market: Distribution by Route of Administration, 2019-2030 (By Volume)
11.3.2.3. Global Novel Vaccine Delivery Device Market: Distribution by Type of Vaccine, 2019-2030 (By Volume)
11.3.2.4. Global Novel Vaccine Delivery Device Market: Distribution by Regions, 2019-2030 (By Volume)
11.3.2.4.1. Novel Vaccine Delivery Device Market in North America, 2019-2030 (By Volume)
11.3.2.4.1.1. Novel Vaccine Delivery Devices Market in North America: Distribution by Type of Device, 2019-2030 (By Volume)
11.3.2.4.1.2. Novel Vaccine Delivery Devices Market in North America: Distribution by Route of Administration, 2019-2030 (By Volume)
11.3.2.4.1.3. Novel Vaccine Delivery Devices Market in North America: Distribution by Type of Vaccine, 2019-2030 (By Volume)
11.3.2.4.2. Novel Vaccine Delivery Devices Market in Europe, 2019-2030 (By Volume)
11.3.2.4.2.1. Novel Vaccine Delivery Devices Market in Europe: Distribution by Type of Device, 2019-2030 (By Volume)
11.3.2.4.2.2. Novel Vaccine Delivery Devices Market in Europe: Distribution by Route of Administration, 2019-2030 (By Volume)
11.3.2.4.2.3. Novel Vaccine Delivery Devices Market in Europe: Distribution by Type of Vaccine, 2019-2030 (By Volume)
11.3.2.4.3. Novel Vaccine Delivery Devices Market in Asia Pacific, 2019-2030 (By Volume)
11.3.2.4.3.1. Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Type of Device, 2019-2030 (By Volume)
11.3.2.4.3.2. Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Route of Administration, 2019-2030 (By Volume)
11.3.2.4.3.3. Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Type of Vaccine, 2019-2030 (By Volume)
11.3.2.4.4. Novel Vaccine Delivery Devices Market in Rest of the World, 2019-2030 (By Volume)
11.3.2.4.4.1. Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Type of Device, 2019-2030 (By Volume)
11.3.2.4.4.2. Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Route of Administration, 2019-2030 (By Volume)
11.3.2.4.4.3. Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Type of Vaccine, 2019-2030 (By Volume)
12. EXECUTIVE INSIGHTS
12.1. Chapter Overview
12.2. Vaxess Technologies
12.2.1. Company Snapshot
12.2.1.1. Interview Transcript: Michael Schrader, Chief Executive Officer and Founder
12.3. Iconovo
12.3.1. Company Snapshot
12.3.1.1. Interview Transcript: Mikael Ekstrom and Roger Lassing, Vice Presidents, Business Development
12.4. Innoture
12.4.1. Company Snapshot
12.4.1.1. Interview Transcript: Henry King, Market Intelligence and Development Manager
13. CONCLUDING REMARKS
13.1. Chapter Overview
13.2. Key Takeaways
14. APPENDIX I: TABULATED DATA
15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 Difference Between Vaccines and Small Molecule
Figure 3.2 Classification of Vaccines
Figure 3.3 Routes for Vaccine Administration
Figure 3.4 Routes of Administration for Vaccines
Figure 3.5 Novel Vaccine Delivery Devices
Figure 4.1 Novel Vaccine Delivery Devices: Distribution by Type of Device
Figure 4.2 Novel Vaccine Delivery Devices: Distribution by Route of Administration
Figure 4.3 Novel Vaccine Delivery Devices: Distribution by Type of Device and Route of Administration
Figure 4.4 Novel Vaccine Delivery Devices: Distribution by Drug Delivery Mechanism
Figure 4.5 Novel Vaccine Delivery Devices: Distribution by Type of Device and Drug Delivery Mechanism
Figure 4.6 Novel Vaccine Delivery Devices: Distribution by Nature of Vaccine Administration
Figure 4.7 Novel Vaccine Delivery Devices: Analysis by Type of Device and Nature of Vaccine Administration
Figure 4.8 Novel Vaccine Delivery Devices: Distribution by Speed of Vaccine Administration
Figure 4.9 Novel Vaccine Delivery Devices: Distribution by Type of Device and Speed of Vaccine Administration
Figure 4.10 Novel Vaccine Delivery Devices: Distribution by Self-Administration Potential
Figure 4.11 Novel Vaccine Delivery Devices: Distribution by Type of Device and Self-Administration Potential
Figure 4.12 Novel Vaccine Delivery Devices: Analysis by Availability of Audio / Visual Feedback
Figure 4.13 Novel Vaccine Delivery Devices: Analysis by Type of Device and Availability of Audio / Visual Feedback
Figure 4.14 Novel Vaccine Delivery Devices: Distribution by Device Usability
Figure 4.15 Novel Vaccine Delivery Devices: Distribution by Type of Device and Device Usability
Figure 4.16 Novel Vaccine Delivery Devices: Distribution by Type of Needle
Figure 4.17 Novel Vaccine Delivery Devices: Analysis by Type of Device and Type of Needle
Figure 4.18 Novel Vaccine Delivery Devices: Distribution by Stage of Development
Figure 4.19 Novel Vaccine Delivery Devices: Distribution by Type of Device and Stage of Development
Figure 4.20 Novel Vaccine Delivery Device Developers: Distribution by Type of Developer
Figure 4.21 Novel Vaccine Delivery Device Developers: Distribution by Year of Establishment
Figure 4.22 Novel Vaccine Delivery Device Developers: Distribution by Company Size
Figure 4.23 Novel Vaccine Delivery Device Developers: Distribution by Geographical Location
Figure 5.1 Novel Vaccine Delivery Devices: Dot Plot Analysis
Figure 5.2 Device Competitiveness Analysis: Novel vaccine Delivery Devices
Figure 6.1 Technology Effectiveness: Analysis by Type of Active Ingredient
Figure 6.2 Technology Effectiveness: Analysis by Route of Administration
Figure 6.3 Technology Effectiveness: Analysis by Target Patient Population
Figure 6.4 Technology Effectiveness: Analysis by Type of Active Ingredient
Figure 6.5 Technology Effectiveness: Analysis by Route of Administration
Figure 6.6 Technology Effectiveness: Analysis by Target Patient Population
Figure 8.1 3M: Annual Revenues, 2015-Q3 2019 (USD Billion)
Figure 8.2 3M™ Hollow Microstructured Transdermal System: Approval Process
Figure 8.3 3M™ Hollow Microstructured Transdermal System: Advantages
Figure 8.4 Solid Microneedle: Advantages
Figure 8.5 Becton Dickinson: Annual Revenues, 2014-Q3 2019 (USD Billion)
Figure 8.6 Consort Medical: Annual Revenues, 2015-2019 (GBP Million)
Figure 8.7 Consort Medical: Syrina® Autoinjectors
Figure 8.8 LectraJet® HS High Speed Jet Injection: Features
Figure 8.9 ImplaVax®: Components
Figure 8.10 ImplaVax®: Features
Figure 8.11 Ichor Medical Systems: Electroporation-based Vaccine Delivery
Figure 8.12 Iconovo: Dry Powder Inhalers
Figure 8.13 Inovio Pharmaceutical: Annual Revenues, 2014-Q3, 2019 (USD Million)
Figure 8.14 PhrmaJet Tropis Intradermal Injection: Administration Steps
Figure 8.15 Union Medico: Types of 45ËšAutoinjector
Figure 8.16 Union Medico: Components of 45Ëš/R Autoinjector
Figure 8.17 Union Medico: Types of 90Ëš Autoinjectors
Figure 8.18 Union Medico: Components of Exclusive Autoinjector
Figure 9.1 Partnerships and Collaborations: Distribution by Year, 2014-2019
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Type of Device
Figure 9.4 Partnerships and Collaborations: Year-Wise Trend of Different Novel Type of Devices, 20014-2019
Figure 9.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Device
Figure 9.6 Partnerships and Collaborations: Distribution by Type of Vaccine and Type of Device
Figure 9.7 Partnerships and Collaborations: Distribution by Type of Active Ingredient
Figure 9.8 Partnerships and Collaborations: Distribution by Target Disease Indication
Figure 9.9 Popular Vaccine Delivery Devices: Analysis by Number of Partnerships
Figure 9.10 Partnerships and Collaborations: Most Active Industry Players
Figure 9.11 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 10.1 Novel Vaccine Delivery Devices SWOT Analysis: Overview
Figure 10.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 11.1 Novel Vaccine Delivery Devices Price Estimates (USD Per Unit)
Figure 11.2 Global Novel Vaccine Delivery Devices Market, 2019-2030 (USD Million)
Figure 11.3 Global Novel Vaccine Delivery Devices Market: Distribution by Type of Device, 2019-2030 (USD Million)
Figure 11.4 Global Novel Vaccine Delivery Devices Market: Distribution by Route of Administration, 2019-2030 (USD Million)
Figure 11.5 Global Novel Vaccine Delivery Devices: Distribution by Type of Vaccine, 2019-2030 (USD Million)
Figure 11.6 Global Novel Vaccine Delivery Devices: Distribution by Regions, 2019-2030 (USD Million)
Figure 11.7 Novel Vaccine Delivery Devices Market in North America, 2019-2030 (USD Million)
Figure 11.8 Novel Vaccine Delivery Devices Market in North America: Distribution by Type of Device, 2019-2030 (USD Million)
Figure 11.9 Novel Vaccine Delivery Devices Market in North America: Distribution by Route of Administration, 2019-2030 (USD Million)
Figure 11.10 Novel Vaccine Delivery Devices Market in North America: Distribution by Type of Vaccine, 2019-2030 (USD Million)
Figure 11.11 Novel Vaccine Delivery Devices Market in Europe, 2019-2030 (USD Million)
Figure 11.12 Novel Vaccine Delivery Devices Market in Europe: Distribution by Type of Device, 2019-2030 (USD Million)
Figure 11.13 Novel Vaccine Delivery Devices Market in Europe: Distribution by Route of Administration, 2019-2030 (USD Million)
Figure 11.14 Novel Vaccine Delivery Devices Market in Europe: Distribution by Type of Vaccine, 2019-2030 (USD Million)
Figure 11.15 Novel Vaccine Delivery Devices Market in Asia Pacific, 2019-2030 (USD Million)
Figure 11.16 Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Type of Device, 2019-2030 (USD Million)
Figure 11.17 Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Route of Administration, 2019-2030 (USD Million)
Figure 11.18 Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Type of Vaccine, 2019-2030 (USD Million)
Figure 11.19 Novel Vaccine Delivery Devices Market in Rest of the World, 2019-2030 (USD Million)
Figure 11.20 Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Type of Device, 2019-2030 (USD Million)
Figure 11.21 Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Route of Administration, 2019-2030 (USD Million)
Figure 11.22 Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Type of Vaccine, 2019-2030 (USD Million)
Figure 11.23 Global Novel Vaccine Delivery Devices Market, 2019-2030 (Million Unit)
Figure 11.24 Global Novel Vaccine Delivery Devices Market, Distribution by Type of Device 2019-2030 (Million Unit)
Figure 11.25 Global Novel Vaccine Delivery Devices Market, Distribution by Type of Device, 2019-2030 (Million Unit)
Figure 11.26 Global Novel Vaccine Delivery Devices Market: Distribution by Route of Administration, 2019-2030 (Million Unit)
Figure 11.27 Global Novel Vaccine Delivery Devices Market: Distribution by Type of Vaccine, 2019-2030 (Million Unit)
Figure 11.28 Novel Vaccine Delivery Devices Market in North America, 2019-2030 (Million Unit)
Figure 11.29 Novel Vaccine Delivery Devices Market in North America: Distribution by Type of Device, 2019-2030 (Million Unit)
Figure 11.30 Novel Vaccine Delivery Devices Market in North America: Distribution by Route of Administration, 2019-2030 (Million Unit)
Figure 11.31 Novel Vaccine Delivery Devices Market in North America: Distribution by Type of Vaccine, 2019-2030 (Million Unit)
Figure 11.32 Novel Vaccine Delivery Devices Market in Europe, 2019-2030 (Million Unit)
Figure 11.33 Novel Vaccine Delivery Devices Market in Europe: Distribution by Type of Device, 2019-2030 (Million Unit)
Figure 11.34 Novel Vaccine Delivery Devices Market in Europe: Distribution by Route of Administration, 2019-2030 (Million Unit)
Figure 11.35 Novel Vaccine Delivery Devices Market in Europe: Distribution by Type of Vaccine, 2019-2030 (Million Unit)
Figure 11.36 Novel Vaccine Delivery Devices Market in Asia Pacific, 2019-2030 (Million Unit)
Figure 11.37 Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Type of Device, 2019-2030 (Million Unit)
Figure 11.38 Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Route of Administration, 2019-2030 (Million Unit)
Figure 11.39 Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Type of Vaccine, 2019-2030 (Million Unit)
Figure 11.40 Novel Vaccine Delivery Devices Market in Rest of the World, 2019-2030 (Million Unit)
Figure 11.41 Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Type of Device, 2019-2030 (Million Unit)
Figure 11.42 Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Route of Administration, 2019-2030 (Million Unit)
Figure 11.43 Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Type of Vaccine, 2019-2030 (Million Unit)
Table 3.1 Vaccines: Classification based on Method of Development
Table 3.2 Live Attenuated Vaccines: Commonly Reported Adverse Events
Table 3.3 Inactivated Vaccines: Commonly Reported Adverse Events
Table 3.4 Subunit Vaccines: Commonly Reported Adverse Events
Table 3.5 Toxoid Vaccines: Commonly Reported Adverse Events
Table 3.6 Vaccine Excipients and their Functions
Table 3.7 Vaccine Administration Routes and Type of Delivery Devices used
Table 3.8 Common Pediatric Vaccines and their Routes of Administration
Table 4.1 List of Marketed Vaccines,
Table 4.2 List of Clinical-Stage Vaccines,
Table 4.3 Novel Vaccine Delivery Devices: List of Available / Under Development Products
Table 4.4 Novel Vaccine Delivery Devices: Distribution of Developers
Table 6.1 Technology Effectiveness: Analysis by Dosage Form
Table 6.2 Technology Effectiveness: Analysis by Target Disease Indication
Table 6.3 Technology Effectiveness: Analysis by Dosage Form
Table 6.4 Technology Effectiveness: Analysis by Target Disease Indication
Table 7.1 Marketed Vaccines: Likely Candidates for Delivery via Novel Vaccine Delivery Devices
Table 7.2 Marketed Vaccines: Most Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
Table 7.3 Marketed Vaccines: Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
Table 7.4 Marketed Vaccines: Less Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
Table 7.5 Marketed Vaccines: Least Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
Table 7.6 Marketed Vaccines: Most Likely Candidates for Delivery via Jet Injectors
Table 7.7 Marketed Vaccines: Likely Candidates for Delivery via Jet Injectors
Table 7.8 Marketed Vaccines: Less Likely Candidates for Delivery via Jet Injectors
Table 7.9 Marketed Vaccines: Least Likely Candidates for Delivery via Jet Injectors
Table 7.10 Marketed Vaccines: Most Likely Candidates for Delivery via Microneedle Patches
Table 7.11 Marketed Vaccines: Less Likely Candidates for Delivery via Microneedle Patches
Table 7.12 Marketed Vaccines: Least Likely Candidates for Delivery via Microneedle Patches
Table 7.13 Marketed Vaccines: Most Likely Candidates for Delivery via Nasal Delivery Systems
Table 7.14 Marketed Vaccines: Likely Candidates for Delivery via Nasal Delivery Systems
Table 7.15 Marketed Vaccines: Less Likely Candidates for Delivery via Nasal Delivery Systems
Table 7.16 Marketed Vaccines: Least Likely Candidates for Delivery via Nasal Delivery Systems
Table 7.17 Marketed Vaccines: Most Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
Table 7.18 Marketed Vaccines: Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
Table 7.19 Marketed Vaccines: Less Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
Table 7.20 Marketed Vaccines: Least Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
Table 7.21 Marketed Vaccines: Most Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
Table 7.22 Marketed Vaccines: Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
Table 7.23 Marketed Vaccines: Less Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
Table 7.24 Marketed Vaccines: Least Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
Table 7.25 Marketed Vaccines: Most Likely Candidates for Delivery via Prefilled Syringes
Table 7.26 Marketed Vaccines: Likely Candidates for Delivery via Prefilled Syringes
Table 7.27 Marketed Vaccines: Less Likely Candidates for Delivery via Prefilled Syringes
Table 7.28 Marketed Vaccines: Least Likely Candidates for Delivery via Prefilled Syringes
Table 7.29 Clinical-Stage Vaccines: Likely Candidates for Delivery Via Novel Vaccine Delivery Devices
Table 7.30 Clinical-Stage Vaccines: Most Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
Table 7.31 Clinical-Stage Vaccines: Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
Table 7.32 Clinical-Stage Vaccines: Less Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
Table 7.33 Clinical-Stage Vaccines: Least Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems\
Table 7.34 Clinical-Stage Vaccines: Most Likely Candidates for Delivery via Jet Injectors
Table 7.35 Clinical-Stage Vaccines: Likely Candidates for Delivery via Jet Injectors
Table 7.36 Clinical-Stage Vaccines: Less Likely Candidates for Delivery via Jet Injectors
Table 7.37 Clinical-Stage Vaccines: Least Likely Candidates for Delivery via Jet Injectors
Table 7.38 Clinical- Stage Vaccines: Most Likely Candidates for Delivery via Microneedle Patches
Table 7.39 Clinical-Stage Vaccines: Likely Candidates for Delivery via Microneedle Patches
Table 7.40 Clinical-Stage Vaccines: Less Likely Candidates for Delivery via Microneedle Patches
Table 7.41 Clinical-Stage Vaccines: Least Likely Candidates for Delivery via Microneedle Patches
Table 7.42 Clinical Vaccines: Most Likely Candidates for Delivery via Nasal Delivery Systems
Table 7.43 Clinical Vaccines: Likely Candidates for Delivery via Nasal Delivery Systems
Table 7.44 Clinical-Stage Vaccines: Less Likely Candidates for Delivery via Nasal Delivery Systems
Table 7.45 Clinical-Stage Vaccines: Least Likely Candidates for Delivery via Nasal Delivery Systems
Table 7.46 Clinical-Stage Vaccines: Most Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
Table 7.47 Clinical-Stage Vaccines: Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
Table 7.48 Clinical-Stage Vaccines: Less Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
Table 7.49 Clinical-Stage Vaccines: Least Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
Table 7.50 Clinical Vaccines: Most Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
Table 7.51 Clinical-Stage Vaccines: Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
Table 7.52 Clinical-Stage Vaccines: Less Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
Table 7.53 Clinical-Stage Vaccines: Least Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
Table 7.54 Clinical-Stage Vaccines: Most Likely Candidates for Delivery via Prefilled Syringes
Table 7.55 Clinical-Stage Vaccines: Likely Candidates for Delivery via Prefilled Syringes
Table 7.56 Clinical-Stage Vaccines: Less Likely Candidates for Delivery via Prefilled Syringes
Table 7.57 Clinical-Stage Vaccines: Least Likely Candidates for Delivery via Prefilled Syringes
Table 8.1 Novel Vaccine Delivery Devices: List of Companies Profiled
Table 8.2 3M: Recent Collaborations
Table 8.3 Becton Dickinson: Medical Devices Portfolio
Table 8.4 Becton Dickinson: Future Outlook
Table 8.5 Consort Medical: Recent Collaborations
Table 8.6 Consort Medical: Future Outlook
Table 8.7 D'Antonio Consultants International: Medical Devices Portfolio
Table 8.8 Enesi Pharma: Recent Collaborations
Table 8.9 Enesi Pharma: Future Outlook
Table 8.10 Ichor Medical Systems: Recent Collaborations
Table 8.11 Ichor Medical Systems: Future Outlook
Table 8.12 Iconovo: Recent Collaborations
Table 8.13 Iconovo: Future Outlook
Table 8.14 Inovio Pharmaceuticals: Recent Collaborations
Table 8.15 Inovio Pharmaceuticals: Future Outlook
Table 8.16 PharmaJet: Recent Collaborations
Table 8.17 PharmaJet: Future Outlook
Table 8.18 Union Medico: Comparison of 45Ëš Autoinjectors
Table 8.19 Union Medico: Comparison of 90Ëš Autoinjectors
Table 9.1 Novel Vaccine Delivery Devices: Partnerships and Collaborations, 2014-2019 (till September),
Table 12.1 Vaxess Technologies: Company Snapshot
Table 12.2 Iconovo: Company Snapshot
Table 12.3 Innoture: Company Snapshot
Table 14.1 Novel Vaccine Delivery Devices: Distribution by Type of Device
Table 14.2 Novel Vaccine Delivery Devices: Distribution by Route of Administration
Table 14.3 Novel Vaccine Delivery Devices: Distribution by Type of Device and Route of Administration
Table 14.4 Novel Vaccine Delivery Devices: Distribution by Drug Delivery Mechanism
Table 14.5 Novel Vaccine Delivery Devices: Distribution by Type of Device and Drug Delivery Mechanism
Table 14.6 Novel Vaccine Delivery Devices: Distribution by Nature of Vaccine Administration
Table 14.7 Novel Vaccine Delivery Devices: Distribution by Type of Device and Nature of Vaccine Administration
Table 14.8 Novel Vaccine Delivery Devices: Distribution by Speed of Vaccine Administration
Table 14.9 Novel Vaccine Delivery Devices: Distribution by Type of Device and Speed of Vaccine Administration
Table14.10 Novel Vaccine Delivery Devices: Distribution by Self Administration Potential
Table 14.11 Novel Vaccine Delivery Devices: Distribution by Type of Device and Self Administration Potential
Table 14.12 Novel Vaccine Delivery Devices: Distribution by Availability of Audio / Visual Feedback
Table 14.13 Novel Vaccine Delivery Devices: Distribution by Type of Device and Availability of Audio / Visual Feedback
Table 14.14 Novel Vaccine Delivery Devices: Distribution by Device Usability
Table 14.15 Novel Vaccine Delivery Devices: Distribution by Type of Device and Device Usability
Table 14.16 Novel Vaccine Delivery Devices: Distribution by Type of Needle
Table 14.17 Novel Vaccine Delivery Devices: Distribution by Type of Device and Type of Needle
Table 14.18 Novel Vaccine Delivery Devices: Distribution by Stage of Development
Table 14.19 Novel Vaccine Delivery Devices: Distribution by Type of Device and Stage of Development
Table 14.20 Novel Vaccine Delivery Device Developers: Distribution by Type of Developer
Table 14.21 Novel Vaccine Delivery Devices Developers: Distribution by Year of Establishment
Table 14.22 Novel Vaccine Delivery Devices Developers: Distribution by Company Size
Table 14.23 Novel Vaccine Delivery Devices Developers: Distribution by Geographical Location
Table 14.24 Technology Effectiveness of Devices for Marketed Vaccines: Analysis by Type of Active Ingredient
Table 14.25 Technology Effectiveness of Devices for Marketed Vaccines: Analysis by Type by Route of Administration
Table 14.26 Technology Effectiveness of Devices for Marketed Vaccines: Analysis by Target Patient Population
Table 14.27 Technology Effectiveness of Devices for Clinical Vaccines: Analysis by Type of Active Ingredient
Table 14.28 Technology Effectiveness of Devices for Clinical Vaccines: Analysis by Rote of Administration
Table 14.29 Technology Effectiveness of Devices for Clinical Vaccines: Analysis by Route of Administration
Table 14.30 3M: Annual Revenues, 2015- Q3 2019 (USD Billion)
Table 14.31 Becton Dickinson: Annual Revenues, 2014- Q3 2019 (USD Billion)
Table 14.32 Consort Medical: Annual Revenues, 2015-2019 (GBP Billion)
Table 14.33 Inovio Pharmaceuticals: Annual Revenues, 2014- Q3 2019 (USD Billion)
Table 14.34 Partnership and Collaborations: Distribution by Year, 2014-2019
Table 14.35 Partnership and Collaborations: Distribution by Type of Partnership
Table 14.36 Partnership and Collaborations: Distribution by Type of Device
Table 14.37 Partnership and Collaborations: Distribution by Year and Type of Device
Table 14.38 Partnership and Collaborations: Distribution by Type of Active Ingredient
Table 14.39 Partnership and Collaborations: Distribution by Target Disease Indication
Table 14.40 Popular Vaccine Delivery Devices: Analysis by Number of Partnerships
Table 14.41 Partnership and Collaborations: Most Active Players
Table 14.42 Novel Vaccine Delivery Devices Price Estimates (USD Per Unit)
Table 14.43 Global Novel Vaccine Delivery Devices Market, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 14.44 Global Novel Vaccine Delivery Devices Market: Distribution by Type of Device, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 14.45 Global Novel Vaccine Delivery Devices Market: Distribution by Route of Administration, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 14.46 Global Novel Vaccine Delivery Devices Market: Distribution by Type of Vaccine, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 14.47 Global Novel Vaccine Delivery Devices Market: Distribution by Regions, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 14.48 Novel Vaccine Delivery Devices Market in North America, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 14.49 Novel Vaccine Delivery Devices Market in North America: Distribution by Type of Device, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 14.50 Novel Vaccine Delivery Devices Market in North America: Distribution by Route of Administration, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 14.51 Novel Vaccine Delivery Devices Market in North America: Distribution by Type of Vaccine, 2019-2030 (USD Million)
Table 14.52 Novel Vaccine Delivery Devices Market in Europe, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 14.53 Novel Vaccine Delivery Devices Market in Europe: Distribution by Type of Device, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 14.54 Novel Vaccine Delivery Devices Market in Europe: Distribution by Route of Administration, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 14.55 Novel Vaccine Delivery Devices Market in Europe: Distribution by Type of Vaccine, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 14.56 Novel Vaccine Delivery Devices Market in Asia Pacific, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 14.57 Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Type of Device, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 14.58 Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Route of Administration, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 14.59 Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Type of Vaccine, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 14.60 Novel Vaccine Delivery Devices Market in Rest of the World, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 14.61 Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Type of Device, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 14.62 Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Route of Administration, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 14.63 Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Type of Vaccine, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 14.64 Global Novel Vaccine Delivery Devices Market, 2019-2030, Conservative, Base and Optimistic Scenario (Million Unit)
Table 14.65 Global Novel Vaccine Delivery Devices Market: Distribution by Type of Device, 2019-2030, Conservative, Base and Optimistic Scenario (Million Unit)
Table 14.66 Global Novel Vaccine Delivery Devices Market: Distribution by Route of Administration, 2019-2030, Conservative, Base and Optimistic Scenario (Million Unit)
Table 14.67 Global Novel Vaccine Delivery Devices Market: Distribution by Type of Vaccine, 2019-2030, Conservative, Base and Optimistic Scenario (Million Unit)
Table 14.68 Global Novel Vaccine Delivery Devices Market: Distribution by Regions, 2019-2030 Conservative, Base and Optimistic Scenario (Million Unit)
Table 14.69 Novel Vaccine Delivery Devices Market in North America, 2019-2030, Conservative, Base and Optimistic Scenario (Million Unit)
Table 14.70 Novel Vaccine Delivery Devices Market in North America: Distribution by Type of Device, 2019-2030, Conservative, Base and Optimistic Scenario (Million Unit)
Table 14.71 Novel Vaccine Delivery Devices Market in North America: Distribution by Route of Administration, 2019-2030, Conservative, Base and Optimistic Scenario (Million Unit)
Table 14.72 Novel Vaccine Delivery Devices Market in North America: Distribution by Type of Vaccine, Conservative, Base and Optimistic Scenario 2019-2030 (Million Unit)
Table 14.73 Novel Vaccine Delivery Devices Market in Europe, 2019-2030, Conservative, Base and Optimistic Scenario (Million Unit)
Table 14.74 Novel Vaccine Delivery Devices Market in Europe: Distribution by Type of Device, 2019-2030, Conservative, Base and Optimistic Scenario (Million Unit)
Table 14.75 Novel Vaccine Delivery Devices Market in Europe: Distribution by Route of Administration, 2019-2030, Conservative, Base and Optimistic Scenario (Million Unit)
Table 14.76 Novel Vaccine Delivery Devices Market in Europe: Distribution by Type of Vaccine, 2019-2030, Conservative, Base and Optimistic Scenario (Million Unit)
Table 14.77 Novel Vaccine Delivery Devices Market in Asia Pacific, 2019-2030, Conservative, Base and Optimistic Scenario (Million Unit)
Table 14.78 Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Type of Device, 2019-2030, Conservative, Base and Optimistic Scenario (Million Unit)
Table 14.79 Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Route of Administration, 2019-2030, Conservative, Base and Optimistic Scenario (Million Unit)
Table 14.80 Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Type of Vaccine, 2019-2030, Conservative, Base and Optimistic Scenario (Million Unit)
Table 14.81 Novel Vaccine Delivery Devices Market in Rest of the World, 2019-2030, Conservative, Base and Optimistic Scenario (Million Unit)
Table 14.82 Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Type of Device, 2019-2030, Conservative, Base and Optimistic Scenario (Million Unit)
Table 14.83 Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Route of Administration, 2019-2030, Conservative, Base and Optimistic Scenario (Million Unit)
Table 14.84 Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Type of Vaccine, 2019-2030, Conservative, Base and Optimistic Scenario (Million Unit)
The following companies and organizations have been mentioned in the report:
Source 1: www.who.int/
Source 2: population.un.org/wpp/Publications/Files/WPP2019_Highlights.pdf